Rocket Lab is Still in the Red. Here Are 4 Reasons to Buy the Stock Anyway.

Rocket Lab has nearly quadrupled over the past 12 months and is scaling launches from 21 Electron missions in 2025 with more than 20 targeted this year, while preparing the larger Neutron rocket for up to 13,000 kg payloads. Analysts expect revenue to rise from $602 million in 2025 to $1.59 billion in 2028, with profitability projected by 2028. The company also won an $816 million SDA contract to build 18 satellites, supporting its shift toward an end-to-end space services model.

Analysis

RKLB is increasingly behaving like a “platform” story rather than a pure launch vendor, and that matters because the multiple is now being underwritten by mix-shift, not unit growth alone. The market is likely still underestimating how much margin can expand if the company moves from low-margin launch services into higher-value satellite, payload integration, and defense-adjacent hardware; that transition typically re-rates aerospace names long before GAAP profitability appears.

The second-order winner is the defense procurement ecosystem. If RKLB can keep converting government wins into multi-year production, the real operating leverage sits with suppliers that scale into repeatable avionics, communications, and propulsion demand; the risk is that a single contract concentration event can create false certainty around the revenue path. A larger Neutron ramp would also shift the competitive map by opening medium-lift missions, but execution risk there is binary: schedule slippage by even 6-12 months would force investors to re-anchor the valuation to Electron-only economics.

The consensus likely underprices how fragile the current narrative is to capital intensity and dilution. At this valuation, any disappointment in launch cadence, gross margin, or Neutron commercialization could compress the multiple faster than revenue can grow, especially if the market starts demanding proof of free cash flow rather than “adjusted” milestones. Conversely, if management can show a credible bridge to positive operating cash flow over the next 12-18 months, the stock can stay expensive longer than skeptics expect because defense-linked backlog tends to support valuation through macro drawdowns.

Near term, this is more of a sentiment and execution trade than a fundamentals trade: the stock can keep trending for quarters, but the asymmetry worsens if the next few catalysts are already priced. The best risk/reward is not chasing outright strength, but expressing a view through defined-risk structures or relative value versus weaker space-adjacent names that lack government backlog or platform expansion optionality.

Key Decisions for Investors

• Buy RKLB on pullbacks only; use a 8-12% correction or a failed breakout as entry, with a 6-12 month horizon. Risk/reward improves if the market gives you a cleaner entry ahead of Neutron or major backlog updates.
• Initiate a defined-risk bullish structure in RKLB, such as a call spread 6-9 months out, to capture re-rating potential while limiting downside if Neutron timing slips. This is preferable to outright stock at a premium multiple.
• Pair long RKLB / short a lower-quality small-cap aerospace or space-services peer with weaker backlog visibility for the next 3-6 months. The trade works if defense demand remains firm but execution risk separates winners from story stocks.
• If already long, trim 20-30% into strength and keep the core position for 12-18 months. At current valuation, incremental upside is likely to come from milestone beats, while downside from delay is sharp and immediate.
• Set a hard watchpoint on Neutron commercialization and gross margin trajectory over the next 2 quarters. If either disappoints, reduce exposure quickly because the multiple is vulnerable to a faster de-rating than revenue growth can offset.